| NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60505-3120-1 | 60505-3120 | HUMAN PRESCRIPTION DRUG | Fenofibrate | Fenofibrate | CAPSULE | ORAL | 20130726 | N/A | ANDA | ANDA202252 | Apotex Corp. | FENOFIBRATE | 43 mg/1 | 100 CAPSULE in 1 BOTTLE (60505-3120-1) |
| 60505-3120-3 | 60505-3120 | HUMAN PRESCRIPTION DRUG | Fenofibrate | Fenofibrate | CAPSULE | ORAL | 20130726 | N/A | ANDA | ANDA202252 | Apotex Corp. | FENOFIBRATE | 43 mg/1 | 30 CAPSULE in 1 BOTTLE (60505-3120-3) |
| 60505-3121-1 | 60505-3121 | HUMAN PRESCRIPTION DRUG | Fenofibrate | Fenofibrate | CAPSULE | ORAL | 20130726 | N/A | ANDA | ANDA202252 | Apotex Corp. | FENOFIBRATE | 130 mg/1 | 100 CAPSULE in 1 BOTTLE (60505-3121-1) |
| 60505-3121-3 | 60505-3121 | HUMAN PRESCRIPTION DRUG | Fenofibrate | Fenofibrate | CAPSULE | ORAL | 20130726 | N/A | ANDA | ANDA202252 | Apotex Corp. | FENOFIBRATE | 130 mg/1 | 30 CAPSULE in 1 BOTTLE (60505-3121-3) |
| 60505-3121-5 | 60505-3121 | HUMAN PRESCRIPTION DRUG | Fenofibrate | Fenofibrate | CAPSULE | ORAL | 20130726 | N/A | ANDA | ANDA202252 | Apotex Corp. | FENOFIBRATE | 130 mg/1 | 500 CAPSULE in 1 BOTTLE (60505-3121-5) |
| 60505-3121-9 | 60505-3121 | HUMAN PRESCRIPTION DRUG | Fenofibrate | Fenofibrate | CAPSULE | ORAL | 20130726 | N/A | ANDA | ANDA202252 | Apotex Corp. | FENOFIBRATE | 130 mg/1 | 90 CAPSULE in 1 BOTTLE (60505-3121-9) |